XML 41 R29.htm IDEA: XBRL DOCUMENT v3.6.0.2
Juno Collaboration and License Agreement (Details) - USD ($)
12 Months Ended
May 04, 2015
Dec. 31, 2016
Dec. 31, 2015
Collaboration agreement      
Issuance of common stock     $ 4,580,000
Juno Therapeutics, Inc      
Collaboration agreement      
Common stock issued 1,000,000    
Research term 4 years    
Minimum annual research payments receivable $ 2,000,000    
Extended term of research 2 years    
Extension fee $ 3,000,000    
Minimum annual payments receivable for extended term of research $ 4,000,000    
Common stock premium percentage on trading price upon exercise of extension 120.00%    
Trailing trading period considered for premium 30 days    
Upfront payments recorded as deferred revenue $ 5,000,000    
Recognition period of deferred revenue 4 years    
Proceeds from sale of common stock $ 8,000,000    
Premium on share price (in dollars per share) $ 3.40    
Aggregate premium on shares issued recorded as deferred revenue $ 3,400,000    
Issuance of common stock $ 4,600,000    
Term of royalties payable after first commercial sale 10 years    
Juno Therapeutics, Inc | Maximum      
Collaboration agreement      
Common stock issued upon exercise of extension $ 10,000,000    
Aggregate milestone payments 51,000,000    
Juno Therapeutics, Inc | Maximum | Third Juno Product      
Collaboration agreement      
Additional aggregate milestone payments 116,000,000    
Juno Therapeutics, Inc | Maximum | Fifth Juno Product      
Collaboration agreement      
Additional aggregate milestone payments 137,500,000    
Juno Therapeutics, Inc | Collaborative Arrangement      
Collaboration agreement      
Proceeds from non refundable upfront fee $ 5,000,000    
Share Price $ 8.00    
Revenue recognized   $ 4,400,000 $ 2,400,000
Aggregate deferred revenue   $ 4,900,000